Pain Management in Patients on Suboxone

Introduction to Pain Management

The American College of Physicians and other medical societies suggest that pain medications can work in patients on Suboxone, but require higher doses and specific management strategies due to buprenorphine's high affinity for mu-opioid receptors that creates competitive blockade of traditional opioid analgesics 1, 2, 3, 4

Buprenorphine is a partial mu-opioid agonist with extremely high receptor affinity but low intrinsic activity, meaning it binds tightly to opioid receptors but produces less effect than full agonists like morphine, creating a "ceiling effect" where additional full opioid agonists must compete for receptor binding, requiring significantly higher doses to achieve analgesia 5, 6, 7, 8
The key principle is that Suboxone maintenance therapy provides minimal to no analgesia for acute pain and should not be relied upon as the primary pain management strategy 5, 9, 10

For mild to moderate acute pain, continue Suboxone and add short-acting full opioid agonists, titrating to higher-than-typical doses to overcome receptor competition, with an expected dose increase of 1.5-2 times the standard opioid dose due to cross-tolerance and receptor blockade 5, 9, 6, 10
For moderate to severe acute pain, split the daily Suboxone dose into every 6-8 hour administration to maximize its analgesic properties, plus add supplemental full opioid agonists, such as morphine or equivalent, titrated to prevent withdrawal first, then achieve analgesia 5, 6, 8, 7
For severe pain or surgical procedures, discontinue Suboxone and transition to full opioid agonist therapy, then reinduct onto Suboxone after pain resolves, using sustained-release and immediate-release morphine or equivalent, titrated to prevent withdrawal first, then achieve analgesia 5, 6, 8, 7
For hospitalized patients with severe acute pain, convert Suboxone to methadone 30-40mg daily, which prevents withdrawal while allowing predictable response to additional opioid analgesics, with methadone binds less tightly to mu receptors than buprenorphine, eliminating the competitive blockade problem 5, 6, 8, 7

Never use mixed agonist-antagonist opioids as they will precipitate acute withdrawal 9, 10
Avoid abrupt discontinuation of Suboxone when switching to full agonists, as this creates increased sensitivity to respiratory depression and sedation from the full agonist 5, 6, 8
Coordinate with the patient's Suboxone prescriber or maintenance program regarding verification of current dose, notification of hospitalization and any controlled substances administered, and discharge planning and medication reconciliation 5, 7, 9, 10

According to the Society for Perioperative Assessment and Quality Improvement, management should be individualized based on the prescribed daily buprenorphine dose, indication for treatment, relapse risk, and expected postoperative pain severity 1, 2, 3, 4
For minor procedures with minimal expected pain, continue Suboxone, while for major procedures with significant expected pain, consider one of the discontinuation strategies above 1, 2, 3
Be aware of multiple drug interactions including QT prolongation, serotonin syndrome, and reduced analgesic effect 1, 2, 3

Split the total daily buprenorphine dose into 3–4 administrations every 6–8 hours (e.g., convert a 16 mg once‑daily regimen to 4–6 mg every 6–8 h) to enhance analgesic effect while maintaining opioid blockade. 11
Add a short‑acting full opioid agonist (e.g., morphine or an equivalent) and titrate first to avoid precipitating withdrawal, then titrate upward to achieve adequate pain control. 11
Use buprenorphine dosing ranges of 4–16 mg per day, divided into 8‑hour intervals, when employing the split‑dose strategy. 11

Verify the patient’s current buprenorphine dose before initiating any additional opioid therapy. 11
Notify the prescriber of any hospitalization and of all controlled substances administered during the stay. 11
Include discharge planning and medication reconciliation with the prescriber to ensure continuity of both pain management and opioid‑use disorder treatment. 11

If conventional doses of supplemental opioids fail to relieve pain, conduct a closely monitored trial of higher‑than‑usual opioid doses, recognizing that buprenorphine’s high receptor affinity may block lower‑dose opioids. 11
When maximal buprenorphine dosing plus higher supplemental opioids still does not achieve analgesia, consider either (a) adding a long‑acting potent opioid such as fentanyl, morphine, or hydromorphone, or (b) transitioning the patient from buprenorphine to methadone maintenance therapy. 11

Establish a clear agreement with the patient regarding the number of breakthrough‑pain opioid pills to be dispensed, the allowed frequency of use, and the expected duration of therapy. 11